The expansion will target additional parenteral filling, device assembly and packaging capacity to support increased demand for the company’s diabetes treatment and testing products, according to a Jan. 24 Lilly news release.
Since 2020, Lilly has invested $4 billion into new manufacturing facilities in North Carolina.
“Expanding our operations at Research Triangle Park will accelerate the rate at which we can produce medicines that patients rely on to address serious health challenges like diabetes,” Edgardo Hernandez, Lilly executive vice president and president of Lilly manufacturing operations said. “We’re on track to achieve the goal we shared in November 2022 of doubling incretin capacity by the end of this year, but this investment is key to ensuring even more patients will have access to medicines they need in the future.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
